help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 12, No. 11, 1351-1360, November 2007; doi:10.1634/theoncologist.12-11-1351
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced S...
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tascilar, M.
Right arrow Articles by Sleijfer, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tascilar, M.
Right arrow Articles by Sleijfer, S.

Sarcoma Research Series

The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas

Metin Tascilar, Walter J. Loos, Caroline Seynaeve, Jaap Verweij, Stefan Sleijfer

Department of Medical Oncology, Erasmus University Medical Center Rotterdam-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

Key Words. Soft tissue sarcoma • Ifosfamide • Pharmacology • Chemotherapy • Pharmacokinetics • Adults

Correspondence: Stefan Sleijfer, M.D., Ph.D., Department of Medical Oncology, Erasmus University Medical Center Rotterdam-Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075EA Rotterdam, The Netherlands. Telephone: 31-0-10-4391733; Fax: 31-0-10-4391003; e-mail: s.sleijfer{at}erasmusmc.nl

Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

The treatment outcome of patients with locally advanced and metastatic soft tissue sarcomas is poor. Doxorubicin is regarded as standard treatment, but its use is featured by the occurrence of cardiotoxicity. This hinders the administration of this drug at high doses or in combination with, in theory, attractive newly developed targeted drugs, such as vascular endothelial growth factor (VEGF) pathway inhibitors. The combination of doxorubicin and VEGF pathway inhibitors has been shown to yield an unacceptable high rate of cardiomyopathy. Ifosfamide is the only drug that consistently shows response rates comparable to those of doxorubicin. The lack of cardiotoxicity renders this drug a much more attractive alternative than doxorubicin to be explored at high doses or as part of new drug combinations. This review addresses the clinical pharmacology, metabolism, and present role of ifosfamide in the treatment of locally advanced and/or metastatic soft tissue sarcomas, excluding gastrointestinal stromal tumors, the Ewing-like sarcomas, and other small blue round cell tumors. Furthermore, this review focuses on the anticipated growing role of ifosfamide in the development of new treatment strategies.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl

Copyright © 2007 by AlphaMed Press.